BioSpace News Archive

Zion Pharma Limited, an emerging Chinese biotechnology company focused on the development of brain-penetrable compounds, announced the initiation of its Phase 1 study, in the United States, for its lead program ZN-A-1041.

A number of DNA testing companies are pursuing pro-active measures to carve off a larger market share. And, a number of them have launched saliva-based DNA test kits to plug supply gaps faced due to rapidly increasing demand.

SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, announces that its partner the Serum Institute of India has dosed the first subjects in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19.

KAIST GSI forum explores big questions in the medical and bio-engineering revolution caused by the COVID-19 in fight against infectious diseases and life quality

Aridis Pharmaceuticals, Inc. announced it has reached an agreement with the US Food and Drug Administration to simplify the Company’s AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis.

Quotient Limited, headquartered in Eysins, Switzerland, announced that the Company and Ortho Clinical Diagnostics have signed a binding letter of intent that confirms the termination of their former distribution agreement and related contracts and resolves all their disputes over the former distribution agreement.

Fiscal year 2020 has been a pivotal year for Astrotech Corporation. We had the first sales of our TRACER 1000™ explosives trace detector, we completed a number of successful field trials including a live screening with the U.S. Transportation Security Administration at Miami International Airport, and we signed a key contract with a global shipping and logistics company.

IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines

AIDS Healthcare Foundation condemns the latest series of attempts by drug manufacturers to undermine an essential part of the healthcare safety net, the 340B Drug Pricing Program.